$0.98
▲ +$0.06
(+6.41%)
Vol 132K
4
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$6.6M
ROE
-216.0%
Margin
-47.3%
D/E
899.15
Beta
0.53
52W
$1–$2
Wall Street Consensus
8 analysts · Apr 20262
Strong Buy
5
Buy
1
Hold
0
Sell
0
Strong Sell
87.5%
Buy Rating
Price Chart
Similar Stocks
LPCN
Lipocine Inc
$44.6M
HIND
Vyome Holdings Inc
$19.4M
CURX
Curanex Pharmaceuticals Inc
$9.4M
TRAW
Traws Pharma Inc
$9.0M
JUNS
Jupiter Neurosciences Inc
$35.1M
CVKD
Cadrenal Therapeutics Inc
$15.9M
CALC
CalciMedica Inc
$95.0M
RVPH
Reviva Pharmaceuticals Holdings Inc
$32.1M
HOTH
Hoth Therapeutics Inc
$15.4M
SNES
Senestech Inc
$11.1M
Earnings
Beat rate: 20.0%
Next Report
May 13, 2026
EPS Estimate: $-0.12
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.12 | — | — |
| Dec 2025 | $0.20 | $0.48 | +$0.28 |
| Sep 2025 | $-0.59 | $-0.62 | $-0.03 |
| Jun 2025 | $-0.43 | $-0.57 | $-0.14 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… |
|---|---|---|---|---|---|
| Revenue | $9.0M | $12.6M | $8.6M | $9.0M | $7.0M |
| Net Income | -$5.7M | -$1.4M | -$4.2M | -$5.3M | -$6.6M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | — | -216.0% | -216.0% | -216.0% | -216.0% | -216.0% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -59.0% | -30.3% | -42.3% | -42.3% | -42.3% | -47.3% |
| Gross Margin | 70.7% | 53.3% | 59.0% | 59.0% | 59.0% | 64.4% |
| D/E Ratio | — | 899.15 | 899.15 | 899.15 | 899.15 | 899.15 |
| Current Ratio | 0.96 | 1.40 | 0.96 | 0.96 | 0.96 | 1.15 |
Key Ratios
ROA (TTM)
-94.7%
P/S (TTM)
0.18
P/B
1.9
EPS (TTM)
$-1.84
CF/Share
$-19.36
Rev Growth 3Y
+15.7%
52W High
$1.87
52W Low
$0.54
$0.54
52-Week Range
$1.87
Financial Health
Free Cash Flow
-$3.8M
Net Debt
$1.5M
Cash
$3.4M
Total Debt
$4.9M
As of Sep 30, 2025
How does BFRI compare to Pharmaceuticals peers?
Peer group: Micro-cap Pharmaceuticals (All) · 171 companies
BFRI valuation vs Pharmaceuticals peers
P/E ratio
—
▼
0%
below
peers
(22.4)
vs Peers
vs Industry
Undervalued
P/S ratio
0.2
▼
96%
below
peers
(5.0)
vs Peers
vs Industry
Undervalued
P/B ratio
1.9
▼
10%
below
peers
(2.1)
vs Peers
vs Industry
Fair value
Div yield
—
▼
0%
below
peers
(2.0%)
vs Peers
vs Industry
Low yield
BFRI profitability vs Pharmaceuticals peers
ROE
-216.0%
▼
298%
below
peers
(-54.3%)
vs Peers
vs Industry
Weak
Net margin
-47.3%
▲
0%
above
peers
(-47.4%)
vs Peers
vs Industry
Weak
Gross margin
64.4%
▼
6%
below
peers
(68.3%)
vs Peers
vs Industry
Weak
ROA
-94.7%
▼
153%
below
peers
(-37.4%)
vs Peers
vs Industry
Weak
BFRI financial health vs Pharmaceuticals peers
D/E ratio
899.2
▲
58286%
above
peers
(1.5)
vs Peers
vs Industry
High debt
Current ratio
1.2
▼
66%
below
peers
(3.4)
vs Peers
vs Industry
Low liquidity
Beta
0.5
▼
43%
below
peers
(0.9)
vs Peers
vs Industry
More volatile
BFRI fundamentals radar
BFRI
Peer median
Industry
BFRI profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
BFRI vs peers: key metrics
Insider Activity
NeutralBuys
0
Sells
0
LUEBBERT HERMANN
Chief Executive Officer · Mar 05
137500 shs
LEFFLER EUGENE FREDERICK
Chief Financial Officer · Mar 05
87500 shs
Last 90 days
Top Holders
Top 5: 19.47%Rosalind Advisors, Inc.
9.79%
$934K
AIGH Capital Management LLC
7.86%
$750K
Vanguard Group Inc
0.98%
$93K
Geode Capital Management, L…
0.56%
$54K
Jane Street Group, LLC
0.28%
$27K
As of Dec 31, 2025
Latest News
No related news yet